Conversely, ABT-263/navitoclax-resistant TIS cancer cells show a compensatory MCL-1 upregulation, serving as a resistance mechanism against ABT-263/navitoclax-induced apoptosis (71). This evidence concerns the gene MCL1 and cancer.